Li Guoqing, Director of the Drug Evaluation Center of State Food and Drug Administration inspected YRPG on September 10 with the accompany of Yao Xinzhong, Deputy Director of the Food and Drug Administration of Jiangsu Province, Chen Guanhua, Director of the Municipal Food and Drug Administration, and Xu Jingren, Chairman of Yangtze River Pharmaceutical Group.
The delegation of Li Guoqing reviewed Phase II engineering of the new drug research institution of Jiangsu Province (YRPG) under construction---the 95 Research and Development Building and concerned the construction schedule of the project; afterwards they deepened into the production workshop and high rack warehouse to understand the existing status of the production scale, craftwork flow, product quality and warehouse establishments, etc. in detail. When they saw the modernized production establishment and the production process with order in No. 2 oral solution workshop, Li Guoqing expressed great interests and consulted with the staff now and again about the production capacity of Lanqin Oral Liquid and such key technical issues as the disinfection and the sediment separation, and applauded frequently with nodding.
In the conversazione, Chairman Xu Jingren reported the development profile, the innovation research and development thought and the future development direction of the enterprise. He said YRPG would persist in the development strategy of "simultaneous development of three drugs" in the future several years to facilitate and reinforce the development and strive to realize the sales target over tens of billions within five years; at the meanwhile, more attentions would be paid to the biotech medicines development by starting from the small molecules so as to lay down foundations for developing large molecules biotech medicines; besides, the group would never spared its effort in developing chemicals and still follow the road of integrating imitation with innovation so as to realize the annual sales volume of RMB50billion at the end of "the 12th Five-Year Plan".
"YRPG features rapid development the latest years, which has contributed a lot to the national pharmaceutical industry." Li Guoqing highly praised YRPG's achievements. He pointed out that the pharmaceutical enterprises must advance their research and development to maintain the development stamina. At present, YRPG has been armed with relatively strong research and development capacities and he himself appreciated YRPG's thought of intensifying the Chinese traditional medicine while developing the biotech medicines in a prudent manner. He highlighted that important breakthroughs could be made to the biotech medicines in the future ten years; thus the enterprise shall pay attention to the basic research and technical accumulation in developing the biotech medicines.
As to the drug examination and approval, Li Guoqing communicated with the enterprise's principals. He stated the Drug Evaluation Center of State Food and Drug Administration would expedite its approval schedule as much as possible on the basis of respecting science, technology, laws and regulations so as to support and promote the innovation and development of the national pharmaceutical industry. He encouraged YRPG to make persistent efforts to enlarge and strengthen the enterprise with the scientific and technological innovations and become a large enterprise with hundreds of billions as soon as possible.